BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Diffenderfer MR, Schaefer EJ. The composition and metabolism of large and small LDL. Curr Opin Lipidol. 2014;25:221-226. [PMID: 24811298 DOI: 10.1097/mol.0000000000000067] [Cited by in Crossref: 90] [Cited by in F6Publishing: 38] [Article Influence: 12.9] [Reference Citation Analysis]
Number Citing Articles
1 Fan J, Liu Y, Yin S, Chen N, Bai X, Ke Q, Shen J, Xia M. Small dense LDL cholesterol is associated with metabolic syndrome traits independently of obesity and inflammation. Nutr Metab (Lond) 2019;16:7. [PMID: 30679939 DOI: 10.1186/s12986-019-0334-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
2 Kolderup A, Svihus B. Fructose Metabolism and Relation to Atherosclerosis, Type 2 Diabetes, and Obesity. J Nutr Metab 2015;2015:823081. [PMID: 26199742 DOI: 10.1155/2015/823081] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
3 Kulanuwat S, Tungtrongchitr R, Billington D, Davies IG. Prevalence of plasma small dense LDL is increased in obesity in a Thai population. Lipids Health Dis 2015;14:30. [PMID: 25925050 DOI: 10.1186/s12944-015-0034-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
4 Dansinger ML, Williams PT, Superko HR, Schaefer EJ. Effects of weight change on apolipoprotein B-containing emerging atherosclerotic cardiovascular disease (ASCVD) risk factors. Lipids Health Dis 2019;18:154. [PMID: 31311555 DOI: 10.1186/s12944-019-1094-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zhang Y, Zhu CG, Xu RX, Li S, Li XL, Guo YL, Wu NQ, Gao Y, Qing P, Cui CJ, Sun J, Li JJ. HDL subfractions and very early CAD: novel findings from untreated patients in a Chinese cohort. Sci Rep 2016;6:30741. [PMID: 27489174 DOI: 10.1038/srep30741] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
6 Genua I, Puig N, Miñambres I, Benítez S, Gil P, Grau-Agramunt M, Rivas-Urbina A, Balagué C, Fernández-Alanin S, García-Osuna Á, Pérez A, Sánchez-Quesada JL. Changes in the Composition and Function of Lipoproteins after Bariatric Surgery in Patients with Severe Obesity. J Clin Med 2021;10:1716. [PMID: 33923393 DOI: 10.3390/jcm10081716] [Reference Citation Analysis]
7 Ampuero J, Romero-Gómez M. Assessing cardiovascular risk in hepatitis C: An unmet need. World J Hepatol. 2015;7:2214-2219. [PMID: 26380047 DOI: 10.4254/wjh.v7.i19.2214] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
8 Levy D, Reichert CO, Bydlowski SP. Paraoxonases Activities and Polymorphisms in Elderly and Old-Age Diseases: An Overview. Antioxidants (Basel) 2019;8:E118. [PMID: 31052559 DOI: 10.3390/antiox8050118] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 10.5] [Reference Citation Analysis]
9 Lorenzatti AJ, Toth PP. New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease. Eur Cardiol 2020;15:1-9. [PMID: 32180834 DOI: 10.15420/ecr.2019.06] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 20.0] [Reference Citation Analysis]
10 Renee Ruhaak L, van der Laarse A, Cobbaert CM. Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia. Ann Clin Biochem 2019;56:338-56. [PMID: 30889974 DOI: 10.1177/0004563219827620] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
11 Chapman MJ, Orsoni A, Tan R, Mellett NA, Nguyen A, Robillard P, Giral P, Thérond P, Meikle PJ. LDL subclass lipidomics in atherogenic dyslipidemia: effect of statin therapy on bioactive lipids and dense LDL. J Lipid Res 2020;61:911-32. [PMID: 32295829 DOI: 10.1194/jlr.P119000543] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
12 Parvaresh Rizi E, Baig S, Loh TP, Toh SA, Khoo CM, Tai ES. Two-Hour Postprandial Lipoprotein Particle Concentration Differs Between Lean and Obese Individuals. Front Physiol 2019;10:856. [PMID: 31379592 DOI: 10.3389/fphys.2019.00856] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Rivas-Urbina A, Rull A, Aldana-Ramos J, Santos D, Puig N, Farre-Cabrerizo N, Benitez S, Perez A, de Gonzalo-Calvo D, Escola-Gil JC, Julve J, Ordoñez-Llanos J, Sanchez-Quesada JL. Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide d-[113-122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice. Biomolecules 2020;10:E829. [PMID: 32485898 DOI: 10.3390/biom10060829] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
14 Gursky O. Structural stability and functional remodeling of high-density lipoproteins. FEBS Lett 2015;589:2627-39. [PMID: 25749369 DOI: 10.1016/j.febslet.2015.02.028] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
15 C Thambiah S, Lai LC. Diabetic dyslipidaemia. Pract Lab Med 2021;26:e00248. [PMID: 34368411 DOI: 10.1016/j.plabm.2021.e00248] [Reference Citation Analysis]
16 Qi Y, Liu J, Wang W, Wang M, Zhao F, Sun J, Liu J, Deng Q, Zhao D. High sdLDL Cholesterol can be Used to Reclassify Individuals with Low Cardiovascular Risk for Early Intervention: Findings from the Chinese Multi-Provincial Cohort Study. J Atheroscler Thromb 2020;27:695-710. [PMID: 31666437 DOI: 10.5551/jat.49841] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
17 Brugnara L, Mallol R, Ribalta J, Vinaixa M, Murillo S, Casserras T, Guardiola M, Vallvé JC, Kalko SG, Correig X, Novials A. Improving Assessment of Lipoprotein Profile in Type 1 Diabetes by 1H NMR Spectroscopy. PLoS One 2015;10:e0136348. [PMID: 26317989 DOI: 10.1371/journal.pone.0136348] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
18 Ivanova EA, Myasoedova VA, Melnichenko AA, Grechko AV, Orekhov AN. Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases. Oxid Med Cell Longev 2017;2017:1273042. [PMID: 28572872 DOI: 10.1155/2017/1273042] [Cited by in Crossref: 102] [Cited by in F6Publishing: 79] [Article Influence: 25.5] [Reference Citation Analysis]
19 Faustino AF, Martins IC, Carvalho FA, Castanho MA, Maurer-Stroh S, Santos NC. Understanding Dengue Virus Capsid Protein Interaction with Key Biological Targets. Sci Rep. 2015;5:10592. [PMID: 26161501 DOI: 10.1038/srep10592] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
20 Izar MCO, Fonseca HARD, França CN, Machado VA, Ferreira CEDS, Fonseca FAH. Rare Presentation of Dercum's Disease in a Child with Abnormalities in Lipoprotein Metabolism. Arq Bras Cardiol 2018;111:755-7. [PMID: 30484519 DOI: 10.5935/abc.20180191] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
21 Thongtang N, Diffenderfer MR, Ooi EMM, Barrett PHR, Turner SM, Le NA, Brown WV, Schaefer EJ. Metabolism and proteomics of large and small dense LDL in combined hyperlipidemia: effects of rosuvastatin. J Lipid Res 2017;58:1315-24. [PMID: 28392500 DOI: 10.1194/jlr.M073882] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
22 Puig N, Miñambres I, Benítez S, Gil P, Grau-Agramunt M, Rivas-Urbina A, Pérez A, Sánchez-Quesada JL. Familial Combined Hyperlipidemia (FCH) Patients with High Triglyceride Levels Present with Worse Lipoprotein Function Than FCH Patients with Isolated Hypercholesterolemia. Biomedicines 2020;8:E6. [PMID: 31935793 DOI: 10.3390/biomedicines8010006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
23 Ronsein GE, Vaisar T. Deepening our understanding of HDL proteome. Expert Rev Proteomics 2019;16:749-60. [PMID: 31382838 DOI: 10.1080/14789450.2019.1650645] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
24 Chen Y, Du M, Xu J, Chen D. The small dense LDL particle/large buoyant LDL particle ratio is associated with glucose metabolic status in pregnancy. Lipids Health Dis 2017;16:244. [PMID: 29241449 DOI: 10.1186/s12944-017-0627-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
25 Cartolano FC, Dias GD, de Freitas MCP, Figueiredo Neto AM, Damasceno NRT. Insulin Resistance Predicts Atherogenic Lipoprotein Profile in Nondiabetic Subjects. J Diabetes Res 2017;2017:1018796. [PMID: 28913361 DOI: 10.1155/2017/1018796] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
26 Kang M, Jeong CW, Ku JH, Kwak C, Kim HH. Hypertriglyceridemia is a potential preoperative predictor for biochemical recurrence after radical prostatectomy. PLoS One 2015;10:e0122438. [PMID: 25803284 DOI: 10.1371/journal.pone.0122438] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
27 Grassi G, Di Caprio G, Fimia GM, Ippolito G, Tripodi M, Alonzi T. Hepatitis C virus relies on lipoproteins for its life cycle. World J Gastroenterol. 2016;22:1953-1965. [PMID: 26877603 DOI: 10.3748/wjg.v22.i6.1953] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
28 Nozue T, Hattori H, Ogawa K, Kujiraoka T, Iwasaki T, Hirano T, Michishita I. Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease. Lipids Health Dis 2016;15:165. [PMID: 27658826 DOI: 10.1186/s12944-016-0339-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
29 Borén J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, Daemen MJ, Demer LL, Hegele RA, Nicholls SJ, Nordestgaard BG, Watts GF, Bruckert E, Fazio S, Ference BA, Graham I, Horton JD, Landmesser U, Laufs U, Masana L, Pasterkamp G, Raal FJ, Ray KK, Schunkert H, Taskinen MR, van de Sluis B, Wiklund O, Tokgozoglu L, Catapano AL, Ginsberg HN. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2020;41:2313-30. [PMID: 32052833 DOI: 10.1093/eurheartj/ehz962] [Cited by in Crossref: 188] [Cited by in F6Publishing: 124] [Article Influence: 188.0] [Reference Citation Analysis]
30 Ma S, Xia M, Gao X. Biomarker Discovery in Atherosclerotic Diseases Using Quantitative Nuclear Magnetic Resonance Metabolomics. Front Cardiovasc Med 2021;8:681444. [PMID: 34395555 DOI: 10.3389/fcvm.2021.681444] [Reference Citation Analysis]
31 Ferri N, Ruscica M. Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia. Endocrine 2016;54:588-601. [PMID: 27038318 DOI: 10.1007/s12020-016-0939-0] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 9.0] [Reference Citation Analysis]
32 Wongcharoen W, Sutthiwutthichai S, Gunaparn S, Phrommintikul A. Is non-HDL-cholesterol a better predictor of long-term outcome in patients after acute myocardial infarction compared to LDL-cholesterol? : a retrospective study. BMC Cardiovasc Disord 2017;17:10. [PMID: 28056802 DOI: 10.1186/s12872-016-0450-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
33 Zhang Y, Li S, Xu RX, Zhu CG, Guo YL, Wu NQ, Sun J, Li JJ. Systemic Inflammatory Markers Are Closely Associated with Atherogenic Lipoprotein Subfractions in Patients Undergoing Coronary Angiography. Mediators Inflamm 2015;2015:235742. [PMID: 26688615 DOI: 10.1155/2015/235742] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
34 Ramsden CE, Zamora D, Majchrzak-Hong S, Faurot KR, Broste SK, Frantz RP, Davis JM, Ringel A, Suchindran CM, Hibbeln JR. Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73). BMJ 2016;353:i1246. [PMID: 27071971 DOI: 10.1136/bmj.i1246] [Cited by in Crossref: 177] [Cited by in F6Publishing: 144] [Article Influence: 35.4] [Reference Citation Analysis]
35 Guttman O, Baranovski BM, Schuster R, Kaner Z, Freixo-Lima GS, Bahar N, Kalay N, Mizrahi MI, Brami I, Ochayon DE. Acute-phase protein α1-anti-trypsin: diverting injurious innate and adaptive immune responses from non-authentic threats. Clin Exp Immunol. 2015;179:161-172. [PMID: 25351931 DOI: 10.1111/cei.12476] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 8.5] [Reference Citation Analysis]
36 Catapano AL, Pirillo A, Norata GD. Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials. Br J Pharmacol 2017;174:3973-85. [PMID: 28369752 DOI: 10.1111/bph.13805] [Cited by in Crossref: 67] [Cited by in F6Publishing: 60] [Article Influence: 16.8] [Reference Citation Analysis]
37 Määttä AM, Salminen A, Pietiäinen M, Leskelä J, Palviainen T, Sattler W, Sinisalo J, Salomaa V, Kaprio J, Pussinen PJ. Endotoxemia is associated with an adverse metabolic profile. Innate Immun 2021;27:3-14. [PMID: 33243051 DOI: 10.1177/1753425920971702] [Reference Citation Analysis]
38 Ivanova EA, Bobryshev YV, Orekhov AN. LDL electronegativity index: a potential novel index for predicting cardiovascular disease. Vasc Health Risk Manag 2015;11:525-32. [PMID: 26357481 DOI: 10.2147/VHRM.S74697] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]